# A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

> **NCT06879158** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 50 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** BR3409
- **DRUG:** BR3409-1
- **DRUG:** BR3409-2

## Key facts

- **NCT ID:** NCT06879158
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-10
- **Primary completion:** 2025-01-26
- **Final completion:** 2025-01-26
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06879158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06879158, "A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06879158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*